Alnylam expanded its AI strategy by striking a partnership with Inceptive Nucleics to apply AI foundation models to RNA interference therapeutic design. The three-year strategic collaboration includes $30 million upfront in cash and equity, with milestone payments that could raise deal value to as much as $2 billion. Inceptive’s platform is designed to generate and optimize RNAi-related candidates using models intended to learn biological patterns that can generalize across tasks. Both companies said early exploratory work showed rapid performance in characterizing small interfering RNAs within weeks. The deal signals intensifying competition for AI-enabled drug discovery capabilities at major RNA therapeutics players, particularly as companies aim to boost experimental productivity while enlarging pipelines. For the industry, it also highlights how corporate governance of AI inputs—data quality, model validation, and decision traceability—will become central to translating AI outputs into clinical candidates.